loading
Foghorn Therapeutics Inc stock is traded at $4.15, with a volume of 22,308. It is up +0.48% in the last 24 hours and down -11.11% over the past month. Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$4.14
Open:
$3.99
24h Volume:
22,308
Relative Volume:
0.19
Market Cap:
$231.88M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-1.7735
EPS:
-2.34
Net Cash Flow:
$-119.33M
1W Performance:
-6.09%
1M Performance:
-11.11%
6M Performance:
-46.94%
1Y Performance:
-30.78%
1-Day Range:
Value
$3.99
$4.30
1-Week Range:
Value
$3.88
$4.42
52-Week Range:
Value
$2.9448
$10.25

Foghorn Therapeutics Inc Stock (FHTX) Company Profile

Name
Name
Foghorn Therapeutics Inc
Name
Phone
617-586-3100
Name
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Name
Employee
112
Name
Twitter
Name
Next Earnings Date
2025-03-07
Name
Latest SEC Filings
Name
FHTX's Discussions on Twitter

Compare FHTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
FHTX
Foghorn Therapeutics Inc
4.16 240.25M 34.16M -98.43M -119.33M -2.34
Biotechnology icon
ONC
Beigene Ltd Adr
242.16 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
433.83 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.23 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
586.81 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
74.38 5.92B 0 -153.72M -103.81M -2.00

Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-23-25 Initiated Citizens JMP Mkt Outperform
Jan-30-25 Initiated B. Riley Securities Buy
Sep-03-24 Initiated Jefferies Buy
Aug-19-24 Initiated Evercore ISI Outperform
Mar-28-23 Initiated BofA Securities Buy
Jan-05-23 Initiated BMO Capital Markets Outperform
Nov-22-21 Initiated H.C. Wainwright Buy
Nov-17-20 Initiated Cowen Outperform
Nov-17-20 Initiated Goldman Buy
Nov-17-20 Initiated Morgan Stanley Overweight
Nov-17-20 Initiated Wedbush Outperform
View All

Foghorn Therapeutics Inc Stock (FHTX) Latest News

pulisher
May 22, 2025

Foghorn Therapeutics Inc. to Participate in Major Upcoming Healthcare Conferences in 2025 - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences - GlobeNewswire

May 22, 2025
pulisher
May 20, 2025

10,895 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Acquired by Cubist Systematic Strategies LLC - Defense World

May 20, 2025
pulisher
May 19, 2025

(FHTX) Trading Report - news.stocktradersdaily.com

May 19, 2025
pulisher
May 19, 2025

Q2 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World

May 19, 2025
pulisher
May 19, 2025

Wedbush Expects Weaker Earnings for Foghorn Therapeutics - Defense World

May 19, 2025
pulisher
May 17, 2025

JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics (NASDAQ:FHTX) - Defense World

May 17, 2025
pulisher
May 15, 2025

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates - MSN

May 15, 2025
pulisher
May 15, 2025

FHTX: JMP Securities Reiterates Market Outperform Rating for Fog - GuruFocus

May 15, 2025
pulisher
May 15, 2025

FHTX: JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics | FHTX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Foghorn Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 15, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics: Pioneering Precision Medicine with Innovative Pharmacology and AI Integration - TipRanks

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Inc. reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025
pulisher
May 14, 2025

FHTX Exceeds Revenue Expectations and Advances Pipeline Programs - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Advances FHD-909 Phase 1 Trial - TipRanks

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Inc. SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Advances Cancer Drug Pipeline with Strong Financial Results: Phase 1 Trial Shows Promise - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Holdings Boosted by Wells Fargo & Company MN - Defense World

May 13, 2025
pulisher
May 13, 2025

Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) PT at $12.13 - Defense World

May 13, 2025
pulisher
May 12, 2025

Ted Myles Joins Cellarity as Chief Executive Officer - Stock Titan

May 12, 2025
pulisher
May 12, 2025

Barclays PLC Increases Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 12, 2025
pulisher
May 08, 2025

(FHTX) Trading Advice - news.stocktradersdaily.com

May 08, 2025
pulisher
May 07, 2025

Renaissance Technologies LLC Acquires 22,500 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 07, 2025
pulisher
May 06, 2025

Foghorn Therapeutics’ SWOT analysis: chromatin pioneer’s stock faces clinical hurdles - Investing.com Nigeria

May 06, 2025
pulisher
May 05, 2025

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference - GlobeNewswire

May 05, 2025
pulisher
May 03, 2025

Foghorn Therapeutics (FHTX) Expected to Announce Quarterly Earnings on Monday - Defense World

May 03, 2025
pulisher
May 03, 2025

JPMorgan Chase & Co. Purchases 45,565 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 03, 2025
pulisher
May 02, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Earns Buy Rating from HC Wainwright - Defense World

May 02, 2025
pulisher
May 01, 2025

Foghorn Therapeutics expands board with biotech veterans By Investing.com - Investing.com India

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics expands board with biotech veterans - Investing.com

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics Elects Neil Gallagher, M.D., Ph.D., and Stuart Duty to Board of Directors - Nasdaq

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire

May 01, 2025
pulisher
Apr 29, 2025

Foghorn Therapeutics Presents New Preclinical Data on Selective - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Geode Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

FHTX Unveils Promising Preclinical Data at Cancer Research Confe - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Foghorn Therapeutics Presents Preclinical Data at AACR 2025 - TipRanks

Apr 28, 2025
pulisher
Apr 28, 2025

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update | FHTX Stock News - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update - The Manila Times

Apr 28, 2025
pulisher
Apr 28, 2025

Foghorn Therapeutics Presents New Preclinical Data on - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

Breakthrough Cancer Drug FHD-909 Shows Synergy with Leading Treatments in Lung Cancer Studies - Stock Titan

Apr 28, 2025
pulisher
Apr 26, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Research Coverage Started at JMP Securities - Defense World

Apr 26, 2025
pulisher
Apr 26, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Earns Mkt Outperform Rating from Analysts at Citizens Jmp - Defense World

Apr 26, 2025
pulisher
Apr 23, 2025

This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Apr 23, 2025
pulisher
Apr 23, 2025

JMP Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Market Outperform Recommendation - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Targ - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Target | FHTX Stock News - GuruFocus

Apr 23, 2025
pulisher
Apr 18, 2025

Brokerages Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Price Target at $13.17 - Defense World

Apr 18, 2025
pulisher
Apr 15, 2025

Foghorn Therapeutics to Host Virtual Investor Event to Review Pi - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting | FHTX Stock News - GuruFocus

Apr 15, 2025

Foghorn Therapeutics Inc Stock (FHTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.16
price down icon 17.27%
$31.18
price down icon 3.94%
$578.71
price down icon 0.54%
$285.14
price down icon 1.34%
$4.10
price down icon 2.24%
$72.94
price down icon 0.11%
Cap:     |  Volume (24h):